Emma Walmsley Sells 38,459 Shares of GSK plc (LON:GSK) Stock

GSK plc (LON:GSK) insider Emma Walmsley sold 38,459 shares of GSK stock in a transaction that occurred on Monday, February 17th. The stock was sold at an average price of GBX 1,418 ($17.97), for a total transaction of £545,348.62 ($691,014.47).

Emma Walmsley also recently made the following trade(s):

• On Monday, February 10th, Emma Walmsley sold 120,653 shares of GSK stock. The stock was sold at an average price of GBX 1,453 ($18.41), for a total transaction of £1,753,088.09 ($2,221,348.31).

GSK Stock Performance

Shares of LON GSK opened at GBX 1,419.22 ($17.98) on Friday. The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64. GSK plc has a 12 month low of GBX 1,282.50 ($16.25) and a 12 month high of GBX 1,823.50 ($23.11). The company has a 50 day simple moving average of GBX 1,375.07 and a two-hundred day simple moving average of GBX 1,451.22. The stock has a market cap of £57.59 billion, a price-to-earnings ratio of 22.93, a PEG ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK) last announced its quarterly earnings data on Wednesday, February 5th. The company reported GBX 23.20 ($0.29) EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. As a group, analysts predict that GSK plc will post 175.980975 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on GSK shares. Berenberg Bank lowered their target price on shares of GSK from GBX 1,820 ($23.06) to GBX 1,600 ($20.27) and set a “buy” rating for the company in a research note on Friday, November 29th. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a research note on Tuesday, January 7th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of GBX 1,805.83 ($22.88).

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.